Aevum Zenth's EMEA division drives cross-border innovation, regulatory leadership, and sustainable infrastructure across 35 nations and 3 distinct markets.
Strategic alignment with EU directives, UK innovation hubs, and Middle Eastern infrastructure initiatives.
London & Frankfurt dual-headquarters managing €420B in assets, specializing in cross-border syndication, ESG funds, and regulatory compliance advisory.
Leading clinical trials in Germany, Switzerland, and Ireland. Focus on biologics, rare disease therapeutics, and EU MDR medical device certification.
ESA partnership programs, satellite manufacturing in the UK, and defense contracting aligned with EU Common Security & Defense Policy.
Offshore wind farms in North Sea, smart grid integration across Scandinavia & Iberia, and hydrogen infrastructure in the Gulf states.
Experienced executives driving regional strategy, compliance, and operational excellence.
Targeting infrastructure decarbonization across 12 EU member states with strict ESG alignment and sovereign-backed yield structures.
FinanceFirst EMEA approval for AZ-492, a breakthrough treatment for rare metabolic disorders developed at our Cambridge & Basel R&D centers.
Healthcare1.2GW phase II development in partnership with national grid operators, adding 400 jobs and powering 1.5M European homes annually.
EnergyRegional inquiries, partnership proposals, and investment relations for Europe, Middle East & Africa.